Mode of Action of Teicoplanin
Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.
Drug Label Information | Brands:
Brands of Teicoplanin in Kenya
Targocid®, Sanofi-aventis Kenya
Ticplat® ,Gufic Stridden Biopharma Private Ltd.
Targocid is indicated in adults and in children from birth for the parenteral treatment of the following infections
- complicated skin and soft tissue infections,
- bone and joint infections,
- hospital acquired pneumonia,
- community acquired pneumonia,
- complicated urinary tract infections,
- infective endocarditis,
- peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),
- bacteraemia that occurs in association with any of the indications listed above.
Teicoplanin is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.
Hypersensitivity to teicoplanin or to any of the excipients
ADVERSE DRUG INTERACTIONS:
Infections and infestations
Superinfection (overgrowth of non-susceptible organisms)
Blood and the lymphatic system disorders
Leucopenia, thrombocytopenia, eosinophilia
Immune system disorders
Anaphylactic reaction (anaphylaxis)
Drug reaction with eosinophilia and systemic symptoms (DRESS), anaphylactic shock
Nervous system disorders
Ear and Labyrinth disordersDeafness, hearing loss , tinnitus, vestibular disorder
Respiratory, thoracic and mediastinal disorders
Diarrhoea, vomiting, nausea
Skin and subcutaneous tissue disorders
Rash, erythema, pruritus
Red man syndrome (e.g. Flushing of the upper part of the body)
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, angioedema, dermatitis exfoliative, urticaria
Renal and Urinary disorders
Blood creatinine increased